Page 1,340«..1020..1,3391,3401,3411,342..1,3501,360..»

Scientists Create Tiny Soft Robots That Get Propelled by Muscles And Nerves – Mashable India

Posted: September 25, 2019 at 12:45 am

Researchers have been mixing biology and technology together since quite a long time. We have already seen examples of researchers develop tiny human brains using stem cells. Then we have the lifelike robots that can move, eat, and die using artificial metabolism. Now, researchers have developed new soft robotic devices who can swim around when their neuromuscular tissue gets triggered on light exposure.

SEE ALSO: Scientists Create Titan In A Jar To Answer Questions About the Existence On Saturn's Moon

The study has been published in the Proceedings of the National Academy of Sciences and is led by Taher Saif, mechanical science and engineering professor at the University of Illinois.

As a part of the study, researchers demonstrated a new generation of two-tailed bots that are powered by skeletal muscle tissue and stimulated by on-board motor neurons. These neurons have optogenetic properties, meaning that these neurons fire up to operate the muscles on light exposure.

"We applied an optogenetic neuron cell culture, derived from mouse stem cells, adjacent to the muscle tissue. The neurons advanced towards the muscle and formed neuromuscular junctions, and the swimmer assembled on its own, mentioned Saif. Once the researchers were able to confirm that these neuromuscular tissue of the robots was compatible with synthetic biobot skeletons, they then worked to optimize the swimmer's abilities.

They made use of different computational models to determine which physical attributes in the robots would make them the fastest and most efficient at swimming. They also had to carefully design the scaffold in which these biorobots would grow and interact to achieve locomotive functions.

SEE ALSO: Researchers Create AI Using Just A Sheet of Glass!

Saif and his team are further going to lead the development of these multicellular engineered living systems who can also respond intelligently to environmental cues in the fields of bioengineering and medicine.

Image credit: Michael Vincent/University of Illinois

Visit link:
Scientists Create Tiny Soft Robots That Get Propelled by Muscles And Nerves - Mashable India

Posted in Illinois Stem Cells | Comments Off on Scientists Create Tiny Soft Robots That Get Propelled by Muscles And Nerves – Mashable India

Scientists Built Tiny Robots Powered by Muscles and Nerves – Futurism

Posted: September 25, 2019 at 12:45 am

BioBots

A team of engineers just successfully merged biological life with machinery, building tiny sperm-inspired robots that use living nerve and muscle cells to swim around when exposed to light.

The new robots arent particularly smart their neural function doesnt get any more sophisticated than automatically activating their muscles when a light shines on them, according to a press release. But the successful integration of skeletal muscle and stem cell-derived neurons with machinery is a promising sign for the future of the nascent field of soft robotics.

The mechanical part of the robot comes in the form of a soft scaffolding designed to be compatible with living cells.At approximately one millimeter wide, its about the same size as the head of a pin.

The University of Illinois at Urbana-Champaign engineers modeled various body shapes to discover what would swim well. Eventually, they arrived at a small, cell-like robot with two flagellar tails, according to research published Monday in PNAS.

Just like twins are not truly identical, two machines designed to perform the same function will not be the same, Illinois engineer Taher Saif said in the press release. One may move faster or heal from damage differently from the other a unique attribute of living machines.

The rudimentary machines are hard to control, but the team hopes future models will be a bit smarter, according to the press release.

Down the road, they hope to build swimming robots that can regenerate and perhaps even integrate with medical devices.

READ MORE: Researchers build microscopic biohybrid robots propelled by muscles, nerves [University of Illinois at Urbana-Champaign via TechXplore]

More on soft robotics: This Soft Robot Mimics Plant Tendrils to Creep and Climb

Read more from the original source:
Scientists Built Tiny Robots Powered by Muscles and Nerves - Futurism

Posted in Illinois Stem Cells | Comments Off on Scientists Built Tiny Robots Powered by Muscles and Nerves – Futurism

Vaping and e-cigarette warnings have been hiding in plain sight – ABC News

Posted: September 25, 2019 at 12:45 am

In recent weeks, a crisis has erupted over vaping.

States have issued dire warnings, banned flavored e-cigarettes and tried, along with the federal government, to get to the bottom of what was causing hundreds of mysterious lung illnesses as well as several deaths around the country.

The crisis appeared to come out of nowhere and confusion surrounded it, sparking alarm among parents, health officials and lawmakers alike. At the heart of the issue is what is causing the lung injuries -- 530 at the CDCs last count -- and eight deaths, the last reported in Missouri. While federal officials say most of those with lung injuries have used THC-containing products, the exact cause is not known.

However, the recent warnings are not the first, with statements dating back a decade from major government entities and for years in scientific journals.

E-cigarettes and vaping started gaining popularity first in 2007 and have become more and more common since. With that, the number of official warnings has picked up steadily over time.

Here are some of them:

June 22, 2009: The Tobacco Control Act goes into effect

Then-President Barack Obama signed the Tobacco Control Act into law, which gave the Food and Drug Administration (FDA) the authority to regulate the creation and marketing of tobacco products, but doesnt specifically list or mention e-cigarettes.

July 22, 2009: FDA warns about e-cigarettes

A news release from the U.S. Food and Drug Administration pointed to a laboratory analysis of e-cigarette samples that found they contain carcinogens and toxic chemicals such as diethylene glycol, an ingredient used in antifreeze.

The FDA is concerned about the safety of these products and how they are marketed to the public, Margaret A. Hamburg, M.D., commissioner of food and drugs, said in the news release.

The release went on to note that the products had not been evaluated or approved by the FDA so at this time the agency has no way of knowing, except for the limited testing it has performed, the levels of nicotine or the amounts or kinds of other chemicals that the various brands of these products deliver to the user.

Sept. 24, 2013: National Association of Attorneys General wants regulation

A letter signed by 40 state and territorial attorneys general called for the FDA to test and regulate e-cigarettes, noting how at that time there was so little known about them.

Through television advertising, consumers are led to believe that e-cigarettes are a safe alternative to cigarettes, despite the fact that they are addictive, and there is no regulatory oversight ensuring the safety of e-cigarette ingredients, the National Association of Attorneys General news release stated.

The group noted that unlike cigarettes, there were no age restrictions on e-cigarettes and they had flavors that appeal to younger users.

Dec. 15, 2015: Study questions whether chronic e-cigarette use could cause lung disease

In a study in the American Journal of Physiology, researchers asked if e-cigarette smoke could have similar effects as cigarette smoke in chronic users. While they acknowledged that more study was needed, they concluded that the vapor contains toxic substances, although less so than cigarette smoke.

And they did say that it elicited a biological response in mice in the in the "vast majority" of studies.

2016: Surgeon General releases report about e-cigarette use among youth

The report warns about the significant uptick in popularity among young people in spite of the fact that gaps in scientific evidence do exist.

E-cigarette use among U.S. youth and young adults is now a major public health concern. E-cigarette use has increased considerably in recent years, growing an astounding 900% among high school students from 2011 to 2015, then-Surgeon General Vivek Muthys preface states.

Specifically, the surgeon general warned about nicotine and its effects on the developing brain. "The effects include addiction, priming for use of other addictive substances, reduced impulse control, deficits in attention and cognition, and mood disorders," the report said. There were also warnings for pregnant women and the dangers of ingestion.

But there was also much that was not known. "The health effects and potentially harmful doses of heated and aerosolized constituents of e-cigarette liquidsincluding solvents, flavorants, and toxicantsare not completely understood. However, although e-cigarettes generally emit fewer toxicants than combustible tobacco products, we know that aerosol from e-cigarettes is not harmless," the report said.

May 5, 2016: FDA issues new e-cigarette regulations

The FDA bolstered its regulations of e-cigarettes, adding requirements that affect manufacturing, ingredient labeling and not selling the product to those under the age of 18.

"We have more to do to help protect Americans from the dangers of tobacco and nicotine, especially our youth. As cigarette smoking among those under 18 has fallen, the use of other nicotine products, including e-cigarettes, has taken a drastic leap. All of this is creating a new generation of Americans who are at risk of addiction," then-Health and Human Services Secretary Sylvia Burwell said in a statement.

"Todays announcement is an important step in the fight for a tobacco-free generation -- it will help us catch up with changes in the marketplace, put into place rules that protect our kids and give adults information they need to make informed decisions," Burwell said.

July 7, 2016: American Lung Association warns of 'popcorn lung'

The American Lung Association warned that a chemical found in artificially buttered popcorn, diacetyl -- which caused "deaths and hundreds of cases of bronchiolitis obliterans, a serious and irreversible lung disease" -- was found in "many" e-cigarette flavors. "It is added to "e-juice" liquid by some e-cigarette companies to complement flavorings such as vanilla, maple, coconut and more," the statement said.

"So while diacetyl was swiftly removed from popcorn products since it could cause this devastating disease among factory workers, e-cigarette users are now directly inhaling this harmful chemical into their lungs," the statement said.

Citing a study from Harvard, the ALA said diacetyl was found in 39 of 51 e-cigarette brands it tested and other harmful chemicals -- 2,3 pentanedione and acetoin -- were found as well.

Aug. 8, 2016: FDA gets authority over e-cigarettes

The FDAs deeming rule went into effect for electronic nicotine delivery systems (ENDS), which meant that the Center for Tobacco Products gained regulatory authority over e-cigarettes, vapes and other products.

Since late 2016, FDA has worked at maximal speed to regulate this rapidly evolving class of new tobacco products, but our policies and procedures in this area are still evolving, an FDA overview of their oversight states.

On that date, it became illegal to sell e-cigarettes and other ENDS to people under 18 years old, the FDA stated.

March 5, 2018: Report notes presence of toxic chemicals

A report in the medical journal Pediatrics showed vaping could lead to the presence of concerning levels of toxic chemicals in the bodies of those who smoked as well as vaped or those who just vaped alone.

Almost 100 teens from the San Francisco Bay area were examined in the University of California-San Francisco study: 67 teens used e-cigarettes only, 16 used both e-cigarettes and conventional cigarettes and 20 didn't smoke or vape at all.

Urine and salivary gland testing looked for breakdown products of toxic chemicals that have been associated with cancer -- and found them in both smokers and vapers -- but not those who didnt smoke at all.

June 8, 2018: CDC report notes popularity decrease after massive uptick

In the CDCs Morbidity and Mortality Weekly Report (MMWR), it stated that at this time, e-cigarettes were the most commonly used tobacco product among middle school and high school students.

E-cigarettes had experienced a massive increase in use starting in 2011, but decreased after 2015.

Aug. 13, 2018: Journal suggests that vaping may increase toxic effects of e-liquid

A study in the journal Thorax indicated a "significant increase in cytotoxicity [on certain lung immune cells] caused by the vaping process itself."

The authors noted that exposures of the cells to the vapor during the in vitro experiment "induced many of the same cellular and functional changes...seen in cigarette smokers and patients with COPD."

"While further research is needed to fully understand the effects of e-cigarette exposure in humans in vivo, we suggest continued caution against the widely held opinion that e-cigarettes are safe," the authors said.

Sept. 11, 2018: Retailers warned and manufacturers highlighted

The FDA went so far as to call e-cigarettes an epidemic among children and issued warning letters to retailers over unlawfully selling to minors.

"We're seeing an acceleration in the use of the cigarettes to levels that simply aren't tolerable, then-FDA commissioner Scott Gottlieb told ABC News.

We have access to data that tells us that the growth in youth use of the cigarettes has reached what I'm calling epidemic proportions and we need to step in and take action to try to stem that use to try to bring the rates of use among young people down, particularly high school students, he said at the time.

Sept. 18, 2018: FDA launches e-cigarette prevention campaign

E-cigarettes have become an almost ubiquitous and dangerous trend among youth that we believe has reached epidemic proportions, said Gottlieb.

This troubling reality is prompting us to take even more forceful actions to stem this dangerous trend, including revisiting our compliance policy that extended the compliance dates for manufacturers of certain e-cigarettes, including flavored e-cigarettes, to submit applications for premarket authorization, Gottlieb said in a statement.

Dec. 18, 2018: Surgeon General issues advisory, calls e-cigarette surge cause for great concern

The U.S. surgeon general issued a strong warning against e-cigarette use by young people, called it "unsafe" in any form and termed vaping an "epidemic."

"Two years after my predecessor sounded the alarm bells, youth e-cigarette use has skyrocketed -- so much so today that I am officially declaring e-cigarette use among youth an epidemic in the United States," said U.S. Surgeon General Jerome Adams, known as the "nation's doctor," at a news conference.

An associated CDC report noted that after leveling off a bit in 2016 and 2017, e-cigarette use skyrocketed again in 2018. The report cited the effects of nicotine exposure as well as the dangers of flavored products being marketed to youth.

"And I don't want there to be any misconceptions about this. I don't use that word, epidemic, which means a sudden increase about normally expected numbers, I do not use that word lightly," Adams said.

Aug. 14, 2019: Minneapolis officials call for investigation

The Minnesota Department of Health (MDH) asked health care providers to be on alert for lung diseases related to vaping and e-cigarette use among young adults after a Minnesota hospital reported several severe cases.

Childrens Minnesota hospital has reported four cases of severe lung injury in the Minneapolis area that it says are similar to cases recently reported in Wisconsin and Illinois. The hospital also said it is too early to say whether they are connected.

The patients spent several weeks in the hospital and some were admitted to the intensive care unit for symptoms including shortness of breath, fever, cough, vomiting and diarrhea. Other symptoms reported by some patients included headache, dizziness and chest pain.

Aug. 18, 2019: Federal investigations launched

Federal health officials are investigating potential links between lung illnesses and e-cigarettes.

Since June 28, there have been at least 94 cases reported across several states involving people with "severe pulmonary disease" possibly tied to vaping, with the majority of those affected being teenagers and young adults, according to the U.S. Centers for Disease Control and Prevention.

At least 30 of those cases were reported in Wisconsin, the CDC said in a statement.

Aug. 23, 2019: First possible vaping death reported

An investigation was launched in Illinois into more than 30 cases where individuals experienced respiratory illness after using e-cigarettes or vaping, state officials said.

One such case involved an individual who allegedly recently vaped before being hospitalized with severe respiratory illness. That individual, whose name, gender and age were not publicly released, died, according to Illinois Department of Public Health.

"The severity of illness people are experiencing is alarming and we must get the word out that using e-cigarettes and vaping can be dangerous," IDPH Director Dr. Ngozi Ezike said in the news release.

The type of e-cigarettes used by these individuals were not disclosed.

Sept. 9, 2019: Melania Trump speaks out against e-cigarettes, and movement in New York

First Lady Melania Trump tweeted about vaping, saying she is "deeply concerned about the growing epidemic."

That same day, New York Gov. Andrew Cuomo announced that he wants to ban flavored e-cigarettes amid growing national health concerns about vaping.

The New York Department of Health is also launching an investigation into companies producing vaping substances and will require shops that sell e-cigarettes to post a warning to "let people know this is a risky endeavor," he said.

"This is a frightening public health phenomenon," Cuomo said at a news conference.

As part of the investigation, Cuomo said subpoenas will be issued to learn more about the chemical makeup of vaping products.

He added that "common sense" would suggest that "if you dont know what you are smoking, dont smoke it, and right now we dont know."

Sept. 11: 2019: President Trump calls for ban on flavored e-cigarettes

President Donald Trump, with the first lady at his side, announced that his administration is moving to ban flavored e-cigarette products after a sixth person recently died from a vaping-related lung illness.

"We are looking at vaping strongly, it's very dangerous, children have died and people have died," Trump told reporters in the Oval Office. "We're going to have some very strong rules and regulations."

The president said kids are coming home from school and saying, "Mom, I want to vape."

Sept. 19, 2019: Warning not to buy products from the street

The FDA, working with their criminal investigation unit, says it has collected 150 samples from several states to analyze and is testing for "chemicals, nicotine, THC, opioids, cutting agents, additives, poisons, toxins, pesticides."

The investigators say they did not plan to pursue prosecutions immediately, just that theyre trying to trace the supply chain for the problem vaping products.

Its crucial, they say, that vapers who use those products arent afraid of prosecution, or they wont report information that could help the search.

Those who use vaping products were warned not to add anything to the vape cartridge and not to buy products from the street.

ABC News Stephanie Ebbs, Anne Flaherty, Quinn Owen, Karma Allen, Allie Yang and Meridith McGraw contributed to this report.

Here is the original post:
Vaping and e-cigarette warnings have been hiding in plain sight - ABC News

Posted in Illinois Stem Cells | Comments Off on Vaping and e-cigarette warnings have been hiding in plain sight – ABC News

Head-To-Head Survey: Intrexon (NASDAQ:XON) versus US Stem Cell (NASDAQ:USRM) – Riverton Roll

Posted: September 25, 2019 at 12:43 am

Intrexon (NASDAQ:XON) and US Stem Cell (OTCMKTS:USRM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, earnings, risk, valuation, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Intrexon and US Stem Cell, as provided by MarketBeat.com.

Intrexon currently has a consensus price target of $19.67, indicating a potential upside of 238.79%. Given Intrexons higher probable upside, research analysts clearly believe Intrexon is more favorable than US Stem Cell.

Valuation and Earnings

This table compares Intrexon and US Stem Cells revenue, earnings per share (EPS) and valuation.

US Stem Cell has lower revenue, but higher earnings than Intrexon.

Risk & Volatility

Intrexon has a beta of 2.36, meaning that its share price is 136% more volatile than the S&P 500. Comparatively, US Stem Cell has a beta of 5.02, meaning that its share price is 402% more volatile than the S&P 500.

Insider & Institutional Ownership

75.7% of Intrexon shares are owned by institutional investors. 44.0% of Intrexon shares are owned by insiders. Comparatively, 16.7% of US Stem Cell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Intrexon and US Stem Cells net margins, return on equity and return on assets.

Summary

Intrexon beats US Stem Cell on 7 of the 11 factors compared between the two stocks.

Intrexon Company Profile

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms. The company also provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. It serves health, food, energy, environment, and consumer markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Ares Trading S.A.; Intrexon Energy Partners II, LLC; Intrexon T1D Partners, LLC; AquaBounty Technologies, Inc.; Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

US Stem Cell Company Profile

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.

See the rest here:
Head-To-Head Survey: Intrexon (NASDAQ:XON) versus US Stem Cell (NASDAQ:USRM) - Riverton Roll

Posted in Maryland Stem Cells | Comments Off on Head-To-Head Survey: Intrexon (NASDAQ:XON) versus US Stem Cell (NASDAQ:USRM) – Riverton Roll

Reviewing Intrexon (NASDAQ:XON) & US Stem Cell (NASDAQ:USRM) – Mayfield Recorder

Posted: September 25, 2019 at 12:43 am

Intrexon (NASDAQ:XON) and US Stem Cell (OTCMKTS:USRM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Volatility and Risk

Intrexon has a beta of 2.36, suggesting that its share price is 136% more volatile than the S&P 500. Comparatively, US Stem Cell has a beta of 5.02, suggesting that its share price is 402% more volatile than the S&P 500.

75.7% of Intrexon shares are owned by institutional investors. 44.0% of Intrexon shares are owned by insiders. Comparatively, 16.7% of US Stem Cell shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Intrexon and US Stem Cell, as reported by MarketBeat.

Intrexon currently has a consensus target price of $19.67, indicating a potential upside of 211.18%. Given Intrexons higher probable upside, analysts clearly believe Intrexon is more favorable than US Stem Cell.

Profitability

This table compares Intrexon and US Stem Cells net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Intrexon and US Stem Cells revenue, earnings per share and valuation.

US Stem Cell has lower revenue, but higher earnings than Intrexon.

Summary

Intrexon beats US Stem Cell on 7 of the 11 factors compared between the two stocks.

About Intrexon

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms. The company also provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. It serves health, food, energy, environment, and consumer markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Ares Trading S.A.; Intrexon Energy Partners II, LLC; Intrexon T1D Partners, LLC; AquaBounty Technologies, Inc.; Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

About US Stem Cell

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.

Go here to see the original:
Reviewing Intrexon (NASDAQ:XON) & US Stem Cell (NASDAQ:USRM) - Mayfield Recorder

Posted in Maryland Stem Cells | Comments Off on Reviewing Intrexon (NASDAQ:XON) & US Stem Cell (NASDAQ:USRM) – Mayfield Recorder

Analyzing US Stem Cell (OTCMKTS:USRM) and Intrexon (OTCMKTS:XON) – TechNewsObserver

Posted: September 25, 2019 at 12:43 am

US Stem Cell (OTCMKTS:USRM) and Intrexon (NASDAQ:XON) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership.

Earnings & Valuation

This table compares US Stem Cell and Intrexons revenue, earnings per share and valuation.

US Stem Cell has higher earnings, but lower revenue than Intrexon.

Risk & Volatility

US Stem Cell has a beta of 5.01, indicating that its share price is 401% more volatile than the S&P 500. Comparatively, Intrexon has a beta of 2.37, indicating that its share price is 137% more volatile than the S&P 500.

Institutional and Insider Ownership

75.7% of Intrexon shares are owned by institutional investors. 16.7% of US Stem Cell shares are owned by insiders. Comparatively, 44.0% of Intrexon shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares US Stem Cell and Intrexons net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and target prices for US Stem Cell and Intrexon, as reported by MarketBeat.com.

Intrexon has a consensus price target of $19.67, suggesting a potential upside of 213.16%. Given Intrexons higher probable upside, analysts plainly believe Intrexon is more favorable than US Stem Cell.

Summary

Intrexon beats US Stem Cell on 7 of the 11 factors compared between the two stocks.

About US Stem Cell

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.

About Intrexon

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms. The company also provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. It serves health, food, energy, environment, and consumer markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Ares Trading S.A.; Intrexon Energy Partners II, LLC; Intrexon T1D Partners, LLC; AquaBounty Technologies, Inc.; Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

Receive News & Ratings for US Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for US Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.

Excerpt from:
Analyzing US Stem Cell (OTCMKTS:USRM) and Intrexon (OTCMKTS:XON) - TechNewsObserver

Posted in Maryland Stem Cells | Comments Off on Analyzing US Stem Cell (OTCMKTS:USRM) and Intrexon (OTCMKTS:XON) – TechNewsObserver

Prothena Corporation plc (PRTA)’s Financial Results Comparing With Neuralstem Inc. (NASDAQ:CUR) – The EN Herald

Posted: September 25, 2019 at 12:43 am

Both Prothena Corporation plc (NASDAQ:PRTA) and Neuralstem Inc. (NASDAQ:CUR) are Biotechnology companies, competing one another. We will compare their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Valuation & Earnings

Table 1 demonstrates Prothena Corporation plc and Neuralstem Inc.s gross revenue, earnings per share and valuation.

Profitability

Table 2 provides Prothena Corporation plc and Neuralstem Inc.s net margins, return on assets and return on equity.

Volatility and Risk

A 2.24 beta indicates that Prothena Corporation plc is 124.00% more volatile compared to Standard and Poors 500. Neuralstem Inc. on the other hand, has 1.94 beta which makes it 94.00% more volatile compared to Standard and Poors 500.

Liquidity

Prothena Corporation plcs Current Ratio is 27.9 while its Quick Ratio is 27.9. On the competitive side is, Neuralstem Inc. which has a 3.8 Current Ratio and a 3.8 Quick Ratio. Prothena Corporation plc is better positioned to pay off short and long-term obligations compared to Neuralstem Inc.

Insider and Institutional Ownership

Roughly 92.7% of Prothena Corporation plc shares are held by institutional investors while 4.9% of Neuralstem Inc. are owned by institutional investors. Prothena Corporation plcs share held by insiders are 90.1%. Competitively, Neuralstem Inc. has 1% of its share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Prothena Corporation plc has stronger performance than Neuralstem Inc.

Summary

Prothena Corporation plc beats Neuralstem Inc. on 7 of the 7 factors.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. It is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating Parkinsons disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dn Laoghaire, Ireland.

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The companys stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read more:
Prothena Corporation plc (PRTA)'s Financial Results Comparing With Neuralstem Inc. (NASDAQ:CUR) - The EN Herald

Posted in Maryland Stem Cells | Comments Off on Prothena Corporation plc (PRTA)’s Financial Results Comparing With Neuralstem Inc. (NASDAQ:CUR) – The EN Herald

Artificially Engineering Intestine – Mirage News

Posted: September 25, 2019 at 12:43 am

-Short bowel syndrome is a debilitating condition with few treatment options, and these treatments have limited efficacy. The ability to grow artificial intestine is a coveted goal with the potential to profoundly improve this outlook. Working toward this target, researchers have created an artificial scaffold that mimics the native small intestinal architecture, complete with villi; this scaffold can incorporate intestinal epithelial cells and be successfully implanted in mice while retaining structural integrity. The work is reported in Tissue Engineering, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the article for free through October 17, 2019.

David J. Hackam, Johns Hopkins School of Medicine, Baltimore, MD, and colleagues present their results in an article titled Development of Intestinal Scaffolds that Mimic Native Mammalian Intestinal Tissue.The authors used polyglycerol sebacate to fabricate scaffolds and showed that they have mechanical properties similar to native intestine, are stable in control and digestive media, and can be infiltrated with intestinal epithelial cells for functional intestinal recreation attempts. An additional feature of the scaffold material is its amenability to the future integration of drug and growth factor delivery mechanisms.

Dr. Hackam and his team at Johns Hopkins, Cornell, and Walter Reed, have beautifully mimicked the microarchitecture of native small intestine using a degradable, poly(glycerol sebacate) scaffold, showing that their approach supports functional intestinal epithelial cells for weeks after implantation, says Tissue Engineering Co-Editor-in-Chief John P. Fisher, PhD, Fischell Family Distinguished Professor & Department Chair, and Director of the NIH Center for Engineering Complex Tissues at the University of Maryland. The work has tremendous translational potential.

About the Journal

Tissue Engineering is an authoritative peer-reviewed journal published monthly online and in print in three parts: Part A, the flagship journal published 24 times per year; Part B: Reviews, published bimonthly, and Part C: Methods, published 12 times per year. Led by Co-Editors-in-Chief Antonios G. Mikos, PhD, Louis Calder Professor at Rice University, Houston, TX, and John P. Fisher, PhD, Fischell Family Distinguished Professor & Department Chair, and Director of the NIH Center for Engineering Complex Tissues at the University of Maryland, the Journal brings together scientific and medical experts in the fields of biomedical engineering, material science, molecular and cellular biology, and genetic engineering. Leadership of Tissue Engineering Parts B (Reviews) and Part C (Methods) is provided by Katja Schenke-Layland, PhD, Eberhard Karls University, Tbingen, Heungsoo Shin, PhD, Hanyang University; and John A. Jansen, DDS, PhD, Radboud University, and Xiumei Wang, PhD, Tsinghua University respectively. Tissue Engineering is the official journal of the Tissue Engineering & Regenerative Medicine International Society (TERMIS). Complete tables of content and a sample issue may be viewed on the Tissue Engineering website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Stem Cells and Development, Human Gene Therapy, and Advances in Wound Care. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industrys most widely read publication worldwide. A complete list of the firms 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Read the original:
Artificially Engineering Intestine - Mirage News

Posted in Maryland Stem Cells | Comments Off on Artificially Engineering Intestine – Mirage News

Could Fate Therapeutics, Inc. (FATE) Recover After Forming a Bearish Head & Shoulders Pattern? – The Altcoin Mercury

Posted: September 25, 2019 at 12:42 am

Investors sentiment increased to 1.44 in 2019 Q2. Its up 0.36, from 1.08 in 2019Q1. It is positive, as 10 investors sold Fate Therapeutics, Inc. shares while 33 reduced holdings. 26 funds opened positions while 36 raised stakes. 56.35 million shares or 1.58% more from 55.48 million shares in 2019Q1 were reported.Metropolitan Life Insur Co New York has 20,423 shares. Strs Ohio has invested 0.01% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE). Financial Management Professionals Inc invested in 0.01% or 1,000 shares. Baker Avenue Asset Mngmt L P invested in 0.03% or 20,000 shares. Nuveen Asset Mgmt Ltd Liability Com owns 299,413 shares. Tiverton Asset Management Limited Liability Company, Delaware-based fund reported 8,673 shares. Cubist Systematic Strategies Limited Liability, a Connecticut-based fund reported 4,948 shares. Fmr Limited Co has invested 0.02% in Fate Therapeutics, Inc. (NASDAQ:FATE). 6 are owned by Royal Bancorp Of Canada. 508,841 were reported by Nikko Asset Americas. Columbus Circle Investors holds 0.06% or 115,532 shares. Legal General Grp Public Ltd Company accumulated 10,732 shares or 0% of the stock. Point72 Asset Limited Partnership reported 593,500 shares. Group Inc One Trading Ltd Partnership accumulated 1,464 shares or 0% of the stock. 4,378 were reported by Bancshares Of Montreal Can.

Since September 16, 2019, it had 1 buy, and 0 sales for $15.00 million activity.

The stock of Fate Therapeutics, Inc. (FATE) formed H&S with $16.26 target or 7.00 % below todays $17.48 share price. The 9 months Head & Shoulders indicates high risk for the $1.14 billion company. It was reported on Sep, 24 by Faxor.com. If the $16.26 price target is reached, the company will be worth $80.01 million less.Head-and-shoulders are one of the best chart patterns to trade. They work in bear and bull markets and according to many researchers have very low failure rate. Even thought they have high pullback rate, such patters usually provide good risk-reward entry opportunities. The percentage of stocks meeting price targets is 55%.

The stock increased 0.89% or $0.15 during the last trading session, reaching $17.48. About 106,110 shares traded. Fate Therapeutics, Inc. (NASDAQ:FATE) has risen 152.00% since September 24, 2018 and is uptrending. It has outperformed by 152.00% the S&P500.

Analysts await Fate Therapeutics, Inc. (NASDAQ:FATE) to report earnings on November, 7. They expect $-0.35 earnings per share, down 12.90 % or $0.04 from last years $-0.31 per share. After $-0.36 actual earnings per share reported by Fate Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -2.78 % EPS growth.

Among 3 analysts covering Fate Therapeutics (NASDAQ:FATE), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Fate Therapeutics has $2800 highest and $20 lowest target. $23.75s average target is 35.87% above currents $17.48 stock price. Fate Therapeutics had 10 analyst reports since March 28, 2019 according to SRatingsIntel. Piper Jaffray maintained the stock with Overweight rating in Monday, September 16 report.

More notable recent Fate Therapeutics, Inc. (NASDAQ:FATE) news were published by: Finance.Yahoo.com which released: Hedge Funds Have Never Been This Bullish On Fate Therapeutics Inc (FATE) Yahoo Finance on June 19, 2019, also Benzinga.com with their article: 58 Biggest Movers From Yesterday Benzinga published on September 13, 2019, Finance.Yahoo.com published: What You Must Know About Fate Therapeutics, Inc.s (NASDAQ:FATE) Beta Value Yahoo Finance on May 29, 2019. More interesting news about Fate Therapeutics, Inc. (NASDAQ:FATE) were released by: Nasdaq.com and their article: Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates Nasdaq published on August 06, 2019 as well as Nasdaq.coms news article titled: Interesting FATE Put And Call Options For July 19th Nasdaq with publication date: May 21, 2019.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company has market cap of $1.14 billion. The Companys immuno-oncology product candidates include FATE-NK100, a natural killer cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. It currently has negative earnings. The companys immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read more from the original source:
Could Fate Therapeutics, Inc. (FATE) Recover After Forming a Bearish Head & Shoulders Pattern? - The Altcoin Mercury

Posted in Delaware Stem Cells | Comments Off on Could Fate Therapeutics, Inc. (FATE) Recover After Forming a Bearish Head & Shoulders Pattern? – The Altcoin Mercury

UA plans to build $20M Andrew Weil Center for Integrative Medicine building – Arizona Daily Star

Posted: September 24, 2019 at 7:46 am

The center is one of several new or renovation projects referenced by the university in a pair of capital improvement plans submitted to the Arizona Board of Regents ahead its two-day meeting Thursday and Friday in Flagstaff.

The new 34,000-square-foot Andrew Weil Center for Integrative Medicine would be located northeast of the Highland Parking Garage at East Mabel Street and North Vine Avenue and provide a physical environment that supports the evidence-based philosophy of integrative medicine, according to regents documents.

Weil, a well-known health and wellness guru, is known for his methods, which complement traditional medicine with an emphasis on nutrition, lifestyle, natural therapies, spirituality and the mind-body connection.

Back in March, he pledged $15 million to put his name on the program, which he helped create more than two decades ago.

The money helped establish an endowed chair in integrative medicine, an endowed chair for research in integrative medicine and an endowed program fund for integrative medicine, all of which bear his name.

This gift marks the high point of my career, Weil said during an appearance with UA President Robert C. Robbins.

The $20 million for construction of the project would be funded through gifts, with the goal of having the bulk of the funding by the end of 2019. The current facility is at 655 N. Alvernon Way, where its been since May 2018.

Thats one of two projects included in the schools $62 million, fiscal-year 2021 capital improvement plan submitted to the regents.

The other is a $42 million renovation for the chemistry building nicknamed Old Chemistry to turn it into an integrative teaching hub, according to regents documents.

The Arizona Board of Regents approved the UAs capital improvement plan, which includes long-range ideas to improve Centennial Halls seating, audio and bathrooms.

The chemistry building was originally constructed in 1936 and has an estimated $15 million in deferred maintenance, among the highest of the schools 621 academic and support facilities, according to documents. The renovation would be funded with system revenue bonds and by using a portion of money allotted to the school by regents for deferred maintenance.

The renovation on the chemistry building is necessary because it cannot accommodate the size and scope of modern laboratory needs, said Thomas McDonald, the schools chief of staff to the office of the business affairs. He said the renovations would put the building more in line with the schools strategic plan, which was approved last year.

There are a number of buildings on campus that we have forecasted for years needing deferred maintenance, McDonald said. We have been looking to take those buildings and reintegrate them into a new use on campus.

Both projects would be in the design phase for the majority of 2020, with construction expected to start at the beginning of 2021 and last into 2022, he said.

The UA also submitted a fiscal year 2022-2023 capital improvement plan to regents for approval. The two-year outlook includes projects under consideration but doesnt include cost estimates, funding methods or time frames for completion.

Sign up for our Breaking News newsletter

Get breaking news alerts delivered to your email inbox.

Those projects include renovations to Centennial Hall, including seating, audio, bathroom and ticket office improvements; additional graduate student housing on campus; a hotel and conference center on campus; a new facility for Arizona Public Media, as well as the information, communication and journalism schools; upgrades and repairs at Arizona Stadium; and land acquisition.

The Andrew Weil Center for Integrative Medicine would be located northeast of the Highland Parking Garage.

Its a mixture of academic, research or student-support projects, McDonald said. Its not necessarily the only ones that could come up.

Speaking about Centennial Hall, McDonald said the UA is hoping to modernize the venue for those who attend events and for those who work and perform there. In terms of real estate, he said the university is hoping to account for limited space and rising real estate costs within the current planning boundaries.

McDonald cautioned that the capital improvement plans are fluid and are redone annually on a three-year scale. That outlook changes based on things like gifts to the university as well as shifts in the world, he said.

Every time we can, we take a moment and strategically look at an opportunity, he said. Its a constant forecast.

Old Main, the original building on the campus of the University of Arizona.

University of Arizona students on the steps of Old Main. 1896. HP-168

Hushed conversations and the rustling of papers were replaced by silence in the main reading room of the old University of Arizona Library at 1013 E. University Blvd. On Feb. 25, 1977, the building stood empty as its collections had been moved down the street to the new UA library. Construction on the original building was begun in 1924, and cost $475,000. Three subsequent additions to the building brought the square footage up to 97,000, but its library days were over. The Arizona State Museum moved into the space.

UA students, circa 1891 to 1900.

University of Arizona Old Main 1891. University of Arizona Library Special Collections. HP-165

University of Arizona students spilled out of their fraternities and dormitories for an impromptu snowball fight during the first snowfall in five years, in February 1956. From the book "Jack Sheaffer's Tucson 1945-1965."

The University of Arizona's second official infirmary was a low-slung red-brick building constructed in 1936 on the site of a former military barracks.

Soldiers training for World War I were among the first to use the University of Arizona's first official infirmary. Started in 1919, the infirmary occupied the former home of Reuben R. Schweitzer. Today, the site is occupied by the Koffler Building.

Robert F. Kennedy at the University of Arizona during his campaign tour. March 29, 1968.

Students in 1968 exit the UA's infirmary, which underwent a "face lift" the year before that included a new emergency room and accommodations for 50 beds. The building now houses the Sonett Space Sciences Building.

A 1927 view of the square outside the University of Arizona Main Gate. The drug store stands on the corner of University and Park Avenue.

The University of Arizona cavalry.

Members of the athletic staff at the University of Arizona pose on Jan. 11, 1966 at the Washington meeting of the National Collegiate Athletic Association with Secretary of the Interior Stewart Udall and his brother, Rep. Morris Udall, D-Ariz. From left are: Dick Clausen, the University's athletic director; Secretary Udall; Rep. Udall; and Thomas Hall, faculty athletic representative at the Arizona University. The Udall brothers are from Tucson and graduates of the University of Arizona.

1914-57 Hank Leiber with James Fred "Pop" McKale in the 1930s, the University of Arizona's most-famous coach and first official athletic director. During that time he was twice the baseball coach, and served stints as basketball and football coach. He is a charter member of the Arizona Sports Hall of Fame.

McKale Center from the air in 1976.

McKale Center under construction on June 9, 1971.

South Hall, University of Arizona, 1901.

Students prepare to whitewash the "A" on Sentinel Peak, also known as "A" Mountain, Sept. 19, 1954.

U.S. Navy occupied Bear Down Gym during WWII. University of Arizona Library Special Collections. HP-173

Jubilant University of Arizona players hold their NCAA College Baseball World Series trophy over their heads in victory at Omaha, Nebraska, Saturday, June 19, 1976. Arizona defeated Eastern Michigan, 7-1, to take the 30th National NCAA crown. (AP Photo/Larry Stoddard)

The empty desert stretches out beyond the 40-acre University of Arizona campus in 1922. The buildings identified are (1) Engineering College, built in 1919; (2) Old Main, built in 1891; and (3) Cochise Hall, a dormitory built in 1922. Today the campus has expanded to 180 acres from Park Avenue area to Campbell Avenue. Speedway cuts diagonally across the pictures. The intersection of Speedway and Campbell is marked.

1943: Football was suspended in 1943 and 1944 due to World War II. The Desert yearbook published pages of snapshots of former Wildcats now serving in the military. The campus became home to U.S. Navy cadet pilots, who lived in Yavapai Hall, had classroom instruction campus and flight instruction Gilpin Airfield at Kino and I-10, which is now home to Costco and Walmart.

The Steward Observatory, July 1920. Courtesy University of Arizona library special collections department.

The Steward Observatory circa 1928. Courtesy University of Arizona special collections.

Sorority sisters pose for a picture during Rush Week at University of Arizona in Sept. 1968.

The Old University of Arizona Library.

A 1929 view of the square outside the University of Arizona Main Gate looking towards downtown Tucson. The photo was taken from the library's upper floor.

Nils V. "Swede" Nelson, left, shows Art Luppino the "good sportsmanship" award he will receive at dinner given by the Gridiron Club of Boston on Jan. 8, 1955. Luppino, University of Arizona tailback and one of the highest college scorers the nation has ever produced, was voted the award by sportswriters across the nation. It was the ninth award presented by Nelson, onetime Harvard football great. (AP Photo/Peter J. Carroll)

The beginning of construction of McKale Center dated January 1971, courtesy of the University of Arizona Special Collections.

Dr. Jack C. Copeland holds a Jarvik-7 artificial heart in the operating room of the University of Arizona Medical Center in Tucson, Ariz., on June 26, 1989. (AP Photo/Steve Mecker)

ARCHIVE PHOTO - Aerial view University of Arizona, Bear Down building. February 14, 1929 at 11:05 am.

ARCHIVE PHOTO - Aerial view University of Arizona, Bear Down building and field. Taken at 9:55 am. February 14, 1929.

UA coach Lute Olson hold the Divsion I NCAA Championship trophy with his team from left; Jason Lee, Miles Simon, Jason Terry, Lute, Justin Wessel, and Bennett Davison after they defeated Kentucky in the Final Four in Indianapolis.

Arizona men's basketball coach Lute Olson holds up the NCAA trophy in front of 30,000 fans inside Arizona stadium at the University of Arizona in Tucson, Ariz., Tuesday, April 1, 1997.

Comedian Jay Leno, right, gives University of Arizona head coach Lute Olson a can of "Lute Spray" for his snow-white hair during a taping of the "Tonight Show With Jay Leno," Wednesday, April 2, 1997, at NBC studios in Burbank, California. Olson and his team won the National Championship at the NCAA on Monday against Kentucky.

Nothing like a little deadline pressure in 1963: Gamma Phi Beta sorority members Carole Martin, left, Jackie Ellis and Sharon Boles prepare parts of their Homecoming float for the next day's parade.

Stewart Udall, secretary of the interior under Pres. Lyndon Johnson, speaks to students at the University of Arizona in October, 1968. Udall was a UA graduate. He was stumping for Sen. Hubert Humprhey, the Democratic nominee running for president against Republic Richard Nixon. Udall was one of history's best interior secretaries, working under presidents Kennedy and Johnson, from 1961-69. His brother Morris "Mo" Udall was the beloved U.S. congressman from Southern Arizona. He son Tom is a U.S. senator from New Mexico.

Kappa Sigma fraternity members won first place in the 1958 University of Arizona Homecoming Parade Proposition 200 category with a funeral procession in protest of the controversial ballot initiative to change the name of Arizona State College in Tempe to Arizona State University.

Civil rights leader Julian Bond ponders a questions while talking in the student union at the University of Arizona on Nov. 21, 1968. "The war in Vietnam takes black young men, in ever larger numbers, so crippled in life that they think it better than living in Harlem. With their white comrades, they burn down houses in a war 8,000 miles from home, but cannot live with whites at home."

Lyndon B. Johnson, at the University of Arizona, shepherded social issues through Congress as president, but the GOP took over after he left office.

Anne Waaser of Syracuse, NY. checks here snow skis, hoping for a good winter on Mt. Lemmon. Coeds Bonnie Rahod from Oak Park, Ill., Mary Ellen Frost of Munster, Ind., Anne Waaser of Syracuse, NY., and Ann Page of Las Vegas, NV., shared a dorm room at Sonora Hall at the University of Arizona in 1973.

"Flush Marquette" float in the 1957 UA Homecoming parade in downtown Tucson.

Davis Monthan Air Force Base firefighters spray the area around the engine of an A-7D Corsair II jet fighter after it crashed near the University of Arizona on October 26, 1978 as it was approaching D-M. It crashed on to North Highland Avenue near East Sixth Street missing Mansfeld Junior High School, background, and the UA. A car carrying two sisters was engulfed in flames killing both women. The pilot safely ejected.

Arizona baseball coach Jerry Kindall, left, celebrates with Chip Hale after Arizona beat Florida State 10-2 on June 9, 1986 to win the NCAA College World Series in Omaha.

Arizona players dog pile on each other following their 4-1 victory over South Carolina in Game 2 to win the NCAA College World Series championship in Omaha, Neb., Monday, June 25, 2012.

University of Arizona basketball coach Lute Olson with starting guard Steve Kerr in during a campus celebration of the team's 1988 NCAA Final Four appearance.

Savannah Guthrie in 1992 as a University of Arizona journalism student. The photo was taken for a guest column in the Tucson Citizen.

A snowball fight on the University of Arizona Mall on March 3, 1976.

Anderson Chevron gas station at 745 N. Park Ave. was located near the University of Arizona main gate at Third Street on June 25, 1971.

University of Arizona students listen to a commencement speaker during ceremonies at Arizona Stadium on June 1, 1966.

Arizona Stadium starts to take shape as 10,000 new seats are added to the west side along Vine Street as part of the University of Arizona's $1.4 million addition to structure on April 16, 1965. The completion date for the addition to the stadium was extended a month to October 2, 1965. The Wildcats were scheduled to play New Mexico after opening the season with three away games against Utah, Kansas and Wyoming.

Nearly 1,000 University of Arizona students rioted on May 6, 1965, after male students demanded "panties" at women's dorms. Rocks and bottles were thrown. Sixteen students were arrested.

Pitcher Taryne Mowatt is lifted by teamates after Arizona beat Tennessee during game 3 of their championship series at the 2007 College World Series at ASA Hall of Fame Stadium in Oklahoma City.

Donald Trump with girlfriend Marla Maples at a University of Arizona basketball game at McKale Center in Tucson on Dec. 27, 1990.

Bruce Crow, an engineering student from Yuma, breaks down a graph on a analog machine at the University of Arizona on March 7, 1957. Crow can turn the coordinates of the graph into numbers which can be put on a punch card and analyzed.

University of Arizona students walk around campus mixing occasionally with traffic in front of the Social Sciences building in 1959. Tucson Citizen file.

University of Arizona graduates seek out friends and family in Arizona Stadium during commencement ceremony on May 31, 1969.

University of Arizona quarterback George Malauulu scores against Baylor during the John Hancock Bowl in El Paso, Texas on Dec 31, 1992. Rick Wiley / Tucson Citizen

Alabama Gov George Wallace addresses an audience at the University of Arizona on January 9, 1964. Months before he had already announced his intention to be the presidential nominee for the 1964 Democratic Party. A year before, Wallace famously declared during his oath of office as governor,"...segregation now, segregation tomorrow, segregation forever." Photo by Jon Kamman / Tucson Citizen

UA cheerleaders ride in the back of a 1955 Chevy Bel Air during the 1966 UA Homecoming football game against BYU at Arizona Stadium. It started in 1914, ebbed and flowed through the years due to wars, apathy or societal forces, but it remains strong today: The University of Arizona Homecoming week. See 100 images from 100 years of UA Homecoming at tucson.com/retrotucson

More video from this section

Contact reporter Justin Sayers at jsayers1@tucson.com or 573-4192. Twitter:

@_JustinSayers. Facebook: JustinSSayers.

The rest is here:
UA plans to build $20M Andrew Weil Center for Integrative Medicine building - Arizona Daily Star

Posted in Integrative Medicine | Comments Off on UA plans to build $20M Andrew Weil Center for Integrative Medicine building – Arizona Daily Star

Page 1,340«..1020..1,3391,3401,3411,342..1,3501,360..»